The ROE as of December 2024 (TTM) for Design Therapeutics, Inc. (DSGN) is -18.01%

According to Design Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -18.01%. This represents a change of 298.90% compared to the average of -4.52% of the last 4 quarters.

Design Therapeutics, Inc. (DSGN) Historical ROE (quarterly & annually)

How has DSGN ROE performed in the past?

The mean historical ROE of Design Therapeutics, Inc. over the last ten years is 15.62%. The current -18.01% ROE has changed -215.33% with respect to the historical average. Over the past ten years (40 quarters), DSGN's ROE was at its highest in in the December 2020 quarter at 34.07%. The ROE was at its lowest in in the June 2023 quarter at -6.72%.

Design Therapeutics, Inc. (DSGN) ROE by Quarter and Year

Discovering the peaks and valleys of Design Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Design Therapeutics, Inc. (DSGN) Average ROE

How has DSGN ROE performed in the past?

The current ROE of Design Therapeutics, Inc. (DSGN) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Design Therapeutics, Inc. (DSGN) ROE vs. Peers

How is DSGN’s ROE compared to its peers?

Design Therapeutics, Inc.’s ROE is greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Achilles Therapeutics plc (-54.57%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Magenta Therapeutics, Inc. (-14.27%), greater than Graphite Bio, Inc. (-57.96%), greater than ALX Oncology Holdings Inc. (-93.02%), greater than Aadi Bioscience, Inc. (-71.87%), less than ADC Therapeutics SA (131.30%), greater than AlloVir, Inc. (-78.95%), greater than Gracell Biotechnologies Inc. (-15.56%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Erasca, Inc. (-42.26%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Immunocore Holdings plc (-14.67%), greater than C4 Therapeutics, Inc. (-42.45%),

Build a custom stock screener for Design Therapeutics, Inc. (DSGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Design Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Design Therapeutics, Inc. (DSGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Design Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.